ISPOR 2025 Poster Presentation – Supplementary Material

Poster Title: **Improving Cancer Recurrence Detection using ctDNA Measures in Colorectal, Breast, and Non-small Cell Lung Cancers. Code MT6**

Presented: **Wednesday 14 May @ 10:30 AM - 1:30 PM**

Colorectal Cancer References

1. Parikh, A. R., Van Seventer, E. E., Siravegna, G.,Hartwig, et al. Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer. *Clin Cancer Res.* 27(20); 2021. doi: 10.1158/1078-0432.Ccr-21-0410
2. Chen, G., Peng, J., et al. Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer. *J Hematol Oncol*. 14(1); 2021. doi: 10.1186/s13045-021-01089-z
3. Tarazona, N., Gimeno-Valiente, F., et al. Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer. *Ann Oncol*. 30(11); 2019. doi: 10.1093/annonc/mdz390
4. Fakih, M., Sandhu, J., Wang, C., et al. Evaluation of Comparative Surveillance Strategies of Circulating Tumor DNA, Imaging, and Carcinoembryonic Antigen Levels in Patients With Resected Colorectal Cancer. *JAMA Netw Open*. 5(3); 2022. doi: 10.1001/jamanetworkopen.2022.1093
5. Yuan, Z., Wang, S., Ni, K., et al. Circulating Methylated SEPT9 DNA Analyses to Predict Recurrence Risk and Adjuvant Chemotherapy Benefit in Stage II to III Colorectal Cancer. *Med Sci Monit*. 28; 2022. doi:10.12659/msm.937757
6. Ryoo, S. B., Heo, S., Lim, Y., et al. Personalised circulating tumour DNA assay with large-scale mutation coverage for sensitive minimal residual disease detection in colorectal cancer. *Br J Cancer*. 129(2); 2023. doi: 10.1038/s41416-023-02300-3
7. Benhaim, L., Bouché, O., et al. Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS). *Eur J Cancer.* 159; 2021. doi: 10.1016/j.ejca.2021.09.004
8. Khakoo, S., Carter, P. D., et al. MRI Tumor Regression Grade and Circulating Tumor DNA as Complementary Tools to Assess Response and Guide Therapy Adaptation in Rectal Cancer. *Clin Cancer Res*. 26(1); 2020. doi: 10.1158/1078-0432.Ccr-19-1996
9. Musher, B. L., Melson, J. E., et al. Evaluation of Circulating Tumor DNA for Methylated BCAT1 and IKZF1 to Detect Recurrence of Stage II/Stage III Colorectal Cancer (CRC). *Cancer Epidemiol Biomarkers Prev.* 29(12); 2020. doi: 10.1158/1055-9965.Epi-20-0574
10. Schneegans, S., Lück, L., et al. Pre-analytical factors affecting the establishment of a single tube assay for multiparameter liquid biopsy detection in melanoma patients. *Mol Oncol.* 14(5); 2020. doi: 10.1002/1878-0261.12669
11. Jin, S., Zhu, D., Shao, F., et al. Efficient detection and post-surgical monitoring of colon cancer with a multi-marker DNA methylation liquid biopsy. *Proc Natl Acad Sci USA*. 118(5); 2021. doi: 10.1073/pnas.2017421118
12. Chan, H. T., Nagayama, S., et al. Tumor-informed or tumor-agnostic circulating tumor DNA as a biomarker for risk of recurrence in resected colorectal cancer patients. *Front Oncol*. 12; 2022. doi: 10.3389/fonc.2022.1055968
13. Reinert, T., Henriksen, T. V., et al. Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer. *JAMA Oncol* 5(8); 2019. doi: 10.1001/jamaoncol.2019.0528
14. Wang, Y., Li, L., Cohen, J. D., et al. Prognostic Potential of Circulating Tumor DNA Measurement in Postoperative Surveillance of Nonmetastatic Colorectal Cancer. *JAMA Oncol.* 5(8); 2019. doi: 10.1001/jamaoncol.2019.0512

Breast Cancer References:

1. Garcia-Murillas, I., Chopra, N., et al. Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer. *JAMA Oncol*. 5(10); 2019. doi: 10.1001/jamaoncol.2019.1838
2. Radovich, M., Jiang, G., et al. Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial. *JAMA Oncol*. 6(9); 2020. doi: 10.1001/jamaoncol.2020.2295
3. Lipsyc-Sharf, M., de Bruin, E. C., et al. Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer. *J Clin Oncol*. 40(22); 2022. doi: 10.1200/jco.22.00908
4. Coombes, R. C., Page, K., et al. Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence. *Clin Cancer Res*. 25(14); 2019. doi: 10.1158/1078-0432.Ccr-18-3663
5. Ortolan, E., Appierto, V., et al. Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapy. *ESMO Open.* 6(2); 2021. doi: 10.1016/j.esmoop.2021.100086
6. La Rocca, E., De Santis, M. C., et al. Early stage breast cancer follow-up in real-world clinical practice: the added value of cell free circulating tumor DNA. *J Cancer Res Clin Oncol*. 148(6); 2022. doi: 10.1007/s00432-022-03990-7
7. Turner, N. C., Swift, C., et al. Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer. *Ann Oncol*. 34(2); 2023. doi: 10.1016/j.annonc.2022.11.005
8. Nguyen Hoang, V. A., Nguyen, S. T., et al. Genetic landscape and personalized tracking of tumor mutations in Vietnamese women with breast cancer. *Mol Oncol*. 17(4); 2023. doi: 10.1002/1878-0261.13356

Non-small Cell Lung Cancer References:

1. Chen, K., Yang, F., et al. Individualized tumor-informed circulating tumor DNA analysis for postoperative monitoring of non-small cell lung cancer. *Cancer Cell*. 41(10); 2023. doi: 10.1016/j.ccell.2023.08.010
2. Wang, S., Xia, Z., You, J., et al. Enhanced Detection of Landmark Minimal Residual Disease in Lung Cancer Using Cell-free DNA Fragmentomics. *Cancer Res Commun*. 3(5); 2023. doi: 10.1158/2767-9764.Crc-22-0363
3. Chen, K., Kang, G., Zhang, Z., et al. Individualized dynamic methylation-based analysis of cell-free DNA in postoperative monitoring of lung cancer. *BMC Med*. 21(1); 2023. doi: 10.1186/s12916-023-02954-z
4. Fu, R., Huang, J., Tian, X., et al. Postoperative circulating tumor DNA can refine risk stratification in resectable lung cancer: results from a multicenter study. *Mol Oncol.* 17(5); 2023. doi: 10.1002/1878-0261.13387
5. Vessies, D. C. L., Schuurbiers, M. M. F., van der Noort, V., et al. Combining variant detection and fragment length analysis improves detection of minimal residual disease in postsurgery circulating tumour DNA of stage II-IIIA NSCLC patients. *Mol Oncol*. 16(14); 2022. doi: 10.1002/1878-0261.13267
6. Yang, W., You, N., Jia, M., Yeung, S. J., et al. Undetectable circulating tumor DNA levels correlate with low risk of recurrence/metastasis in postoperative pathologic stage I lung adenocarcinoma patients. *Lung Cancer.* 146 ; 2020. doi: 10.1016/j.lungcan.2020.06.009
7. Li, N., Wang, B. X., Li, J., et al. Perioperative circulating tumor DNA as a potential prognostic marker for operable stage I to IIIA non-small cell lung cancer. *Cancer.* 128(4); 2022. doi: 10.1002/cncr.33985
8. Abbosh, C., Frankell, A. M., Harrison, T., Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA. *Nature*. 616(7957); 2023. doi: 10.1038/s41586-023-05776-4
9. Zhang, J. T., Liu, S. Y., Gao, W., et al. Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non-Small Cell Lung Cancer. *Cancer Discov.* 12(7); 2022. doi: 10.1158/2159-8290.Cd-21-1486